Ceftizoximeに関する基礎的ならびに臨床的研究 (Ceftizoxime<特集>)
スポンサーリンク
概要
- 論文の詳細を見る
Fundamental and clinical studies were performed on ceftizoxime.<BR>Peak seithivity leveleto the drug of clinical isolates of <I>S. aureus, B. coil, Klebsiella, P. mirabilis, P. vulgaris, P. aeruginosa</I> were found at 1.56, <0.1, <0.1, <0.1, 0.1, 25 and <0.1μg/ml, respectively. The drug was thus demonstrated to be less active against S. aureus than CEZ but far greater than CEZ in its antibacterial activity against gram-negative bacilli.<BR>Blood levels of ceftizoxime yielded by the i. v. drip infusion of 1g for 1 hour in healthy adults averaged 49.2μg/ml just after completion of administration, 25.7μg/ml at 30 minutes, 17.7μg/ml at 1 hour, 6.9μg/ml at 3 hours and 2.5μg/ml at 5 hours, with T1/2 being estimated at 1.432 hours. T1/2 of cefotiam as measured under the same conditions was 0.988 hour. Following the administration of 1g of ceftizoxime by i. v. drip infusion for 1 hour 86.7% of the administered dose was recovered in urine within 24 hours.<BR>Fourteen cases of respiratory infection and 7 cases of urinary tract infection were treated with ceftizoxime administered by i. v. drip infusion at a daily dosage of 1 to 4 g for 5 to 22 days. Clinical response to this drug was excellent in 2 cases, good in 7 cases, fair in 3 cases and poor in 2 cases of respiratory tract infection and excellent in 3 cases, good in 3 cases and poor in 1 case of urinary tract infection. Bacteriologically, the result of the treatment was good in 10 cases, poor in 1 case and uncertain^ in 3 cases of respiratory tract infection and good in 2 cases, fair (partially effective) in 1 case, poor in 2 cases and uncertain in 2 cases of urinary tract infection. Of 21 cases, the use of the drug was attended with a transient, slight elevation of GOT and GPT in 3 cases and of BUN in 1 case. Otherwise no noticeable side-effects were encountered.
- 公益社団法人 日本化学療法学会の論文
公益社団法人 日本化学療法学会 | 論文
- DISPOSITION OF 7432-8 IN RATS (I)
- CLINICAL STUDIES ON T-1220 IN SURGICAL CASES
- CLINICAL STUDIES OF PIVALOYLOXYMETHYL D-α-AMINOBENZYL-PENICILLINATE HYDROCHLORIDE IN SURGICAL INFECTIONS
- STUDIES ON AC-1370
- Primary treatment with a combination of cyclophosphamide, vincristine, and dacarbazine for recurrent malignant pheochromocytoma: A case report.